ICU Medical Inc
SWB:IC7

Watchlist Manager
ICU Medical Inc Logo
ICU Medical Inc
SWB:IC7
Watchlist
Price: 143 EUR -1.38% Market Closed
Market Cap: €3.5B

Wall St Price Targets

IC7 Price Targets Summary
ICU Medical Inc

Wall Street analysts forecast IC7 stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IC7 is 140.45 EUR with a low forecast of 128.49 EUR and a high forecast of 163.9 EUR.

Lowest Forecast
Price Target
128.49 EUR
10% Downside
Average Forecast
Price Target
140.45 EUR
2% Downside
Highest Forecast
Price Target
163.9 EUR
15% Upside
ICU Medical Inc Competitors:
Price Targets
9930
Horizon Construction Development Ltd
72% Upside
RVTY
Revvity Inc
0% Upside
XLO
Xilio Therapeutics Inc
125% Upside

Revenue
Forecast

16% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss
16% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
0%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 16%. The projected CAGR for the next 5 years is 5%.

Gross Profit
Forecast

14% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
14% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 14%. The projected CAGR for the next 5 years is 8%.

Operating Income
Forecast

5% / Year
Past Growth
56% / Year
Estimated Growth
Estimates Accuracy
-23%
Average Miss
5% / Year
Past Growth
56% / Year
Estimated Growth
Estimates Accuracy
-23%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 56%.

Pre-Tax Income
Forecast

-18% / Year
Past Growth
330% / Year
Estimated Growth
Estimates Accuracy
-40%
Average Miss
-18% / Year
Past Growth
330% / Year
Estimated Growth
Estimates Accuracy
-40%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -18%. The projected CAGR for the next 3 years is 330%.

Net Income
Forecast

-27% / Year
Past Growth
240% / Year
Estimated Growth
Estimates Accuracy
-27%
Average Miss
-27% / Year
Past Growth
240% / Year
Estimated Growth
Estimates Accuracy
-27%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been -27%. The projected CAGR for the next 5 years is 240%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is IC7's stock price target?
Price Target
140.45 EUR

According to Wall Street analysts, the average 1-year price target for IC7 is 140.45 EUR with a low forecast of 128.49 EUR and a high forecast of 163.9 EUR.

What is the Revenue forecast for ICU Medical Inc?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 16%. The projected CAGR for the next 5 years is 5%.

What is the Gross Profit forecast for ICU Medical Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 14%. The projected CAGR for the next 5 years is 8%.

What is the Operating Income forecast for ICU Medical Inc?
Projected CAGR
56%

Over the last 13 years, the compound annual growth rate for Operating Income has been 5%. The projected CAGR for the next 3 years is 56%.

What is the Pre-Tax Income forecast for ICU Medical Inc?
Projected CAGR
330%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been -18%. The projected CAGR for the next 3 years is 330%.

What is the Net Income forecast for ICU Medical Inc?
Projected CAGR
240%

Over the last 13 years, the compound annual growth rate for Net Income has been -27%. The projected CAGR for the next 5 years is 240%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett